Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

> 39 degrees C 33.3% (1/3) 40.0% (2/5) ------------------------------------------------------------------------- Albumin ------------------------------------------------------------------------- < =25 mg/mL 22.2% (8/36) 31.5% (17/54) 26-35 mg/mL 10.0% (9/90) 23.3% (20/86) ------------------------------------------------------------------------- Strain Type ------------------------------------------------------------------------- Non-BI (NAP1/027) 7.8% (8/103) 25.5% (27/106) -------------------------------------------------------------------------

Dr. Miller also presented the previously announced top-line results and data related to patient status (in-patient/out-patient), age (under/over 65) and the strain type BI (NAP1/027).

"The subgroup analysis shows that fidaxomicin is more effective than oral vancomycin when it comes to reducing recurrence, even in high risk patient populations such as those older than 65, hospitalized patients, and patients with very low albumin levels," said Mark A. Miller, M.D., Chief of Clinical Microbiology, Head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at Jewish General Hospital and Associate Professor of Medicine and Microbiology/Immunology at McGill University in Montreal, Quebec, Canada.

Additional analyses from this study will be presented at medical conferences throughout the year.

Fidaxomicin Clinical Study Design

629 adult subjects were enrolled in this multi-center, randomized, double-blind Phase 3 clinical trial, which was the largest such trial for the treatment of CDI. Subjects with confirmed CDI received either 200 mg fidaxomicin dosed orally twice daily or 125 mg Vancocin dosed orally four times daily
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... TEL AVIV, Israel, BADAJOZ, Spain and SINGAPORE, August 5 ... been appointed as the,new Chief Executive Officer effective July ... 20 years of experience in sales,marketing and senior management ... VP of Marketing and Sales at UltraShape Ltd., a ...
... Lai-Goldman, Chief Medical Officer of LabCorp and Jack Ballantyne, ... ... Team, CARLSBAD, Calif., Aug. 5 GenVault Corporation ... Lai-Goldman and,Dr. Jack Ballantyne, have joined its Scientific Advisory ...
... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,will hold ... Chairman and CEO, at,12:00pm EDT today, August 5, ... to discuss the preliminary results obtained from its,open-label, ...
Cached Biology Technology:Pollogen Announces Appointment of Ms. Yfat Scialom as Chief Executive Officer 2GenVault Expands Scientific Advisory Board 2GenVault Expands Scientific Advisory Board 3NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER 2
(Date:7/10/2014)... Foundation, a nonprofit organization funding cutting-edge, innovative research ... glaucoma and macular degeneration, today announced the recipients ... scientists in 19 U.S. states, the District of ... . , With these latest grants, BrightFocus ... research funding in 2014. , The research projects ...
(Date:7/10/2014)... ANN ARBOR Because the strong currents in the ... rupture of the oil pipeline beneath the channel would ... and Huron, according to a new University of Michigan ... one scenario examined in the study and accompanying animations, ... and Round Island after 12 hours and Bois Blanc ...
(Date:7/10/2014)... University Medical Center (CUMC) researchers have created a way ... pigmentosa (RP), a leading cause of vision loss. The ... induced pluripotent stem (iPS) cell technology to transform skin ... a patient-specific model for disease study and preclinical testing. ... Tsang, MD, PhD, showed that a form of RP ...
Breaking Biology News(10 mins):BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
... Functioning much like gears in a machine, cellular motor ... including muscle contraction, cell migration and cellular growth processes. ... of The Scripps Research Institute report that motor proteins ... long-term memories. The findings add an unexpected dimension to ...
... twin awards from the National Science Foundation (NSF) totaling ... Computational Sciences (NICS) will add 300 teraflops to the ... have access to more than 200 million additional service ... available from NICS to over 800 million and benefitting ...
... from the U.S., the researchers surrounding Prof. Dr. Martina Havenith ... a so-termed Rapid Communication in the prestigious American chemistry journal, ... The journal,s independent reviewers evaluated the work as one of ... household antifreeze Temperatures of minus 1.8 C ...
Cached Biology News:UCI-Scripps study links cellular motors to memory 2NICS to add more than 300 Teraflops to the NSF’s computing capacity 2Why fish don't freeze in the Arctic Ocean 2
Protein Marker Detection Pack contains biotinylate...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: